Terms: = Leukemia AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306 AND Prognosis
20 results:
1. [Expression and Clinical Significance of Helper T Cells 9 and Its Sytokines Interleukin 9 in Chronic Lymphocytic leukemia].
Shabaaiti T; Pang NN; Xierenguli A; Nazhakaiti Y; Guo S; Zhang RR; Gong S; Qu JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1663-1669. PubMed ID: 38071043
[TBL] [Abstract] [Full Text] [Related]
2. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with irf4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract] [Full Text] [Related]
3. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
Kameda T; Kataoka K; Kamiunten A; Hidaka M; Miyoshi H; Nakano N; Nosaka K; Yoshimitsu M; Yasunaga JI; Kogure Y; Shide K; Miyahara M; Sakamoto T; Akizuki K; Hidaka T; Kubuki Y; Koya J; Kawano N; Yamashita K; Kawano H; Toyama T; Maeda K; Marutsuka K; Imaizumi Y; Kato K; Sugio T; Tokunaga M; Tashiro Y; Takaori-Kondo A; Miyazaki Y; Akashi K; Ishitsuka K; Matsuoka M; Ohshima K; Watanabe T; Kitanaka A; Utsunomiya A; Ogawa S; Shimoda K
Haematologica; 2023 Aug; 108(8):2178-2191. PubMed ID: 36794502
[TBL] [Abstract] [Full Text] [Related]
4. irf4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid leukemia from Another Perspective.
Tarantini F; Cumbo C; Parciante E; Anelli L; Zagaria A; Coccaro N; Minervini CF; Tota G; Redavid I; Conserva MR; Attolico I; Rossi AR; Specchia G; Musto P; Albano F
Acta Haematol; 2023; 146(1):37-43. PubMed ID: 36195064
[TBL] [Abstract] [Full Text] [Related]
5. Alvocidib inhibits irf4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.
Sakamoto H; Ando K; Imaizumi Y; Mishima H; Kinoshita A; Kobayashi Y; Kitanosono H; Kato T; Sawayama Y; Sato S; Hata T; Nakashima M; Yoshiura KI; Miyazaki Y
Cancer Sci; 2022 Dec; 113(12):4092-4103. PubMed ID: 36047964
[TBL] [Abstract] [Full Text] [Related]
6. ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.
Luchtel RA; Zhao Y; Aggarwal RK; Pradhan K; Maqbool SB
Blood Adv; 2022 Oct; 6(20):5613-5624. PubMed ID: 35675522
[TBL] [Abstract] [Full Text] [Related]
7. Correlation of the transcription factors
Zhang Y; Zeng X; Zha X; Lai J; Tan G; Chen S; Yu X; Li Y; Xu L
Hematology; 2022 Dec; 27(1):523-529. PubMed ID: 35544467
[TBL] [Abstract] [Full Text] [Related]
8. Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.
Kataoka K; Koya J
J Clin Exp Hematop; 2020 Sep; 60(3):66-72. PubMed ID: 32779615
[TBL] [Abstract] [Full Text] [Related]
9. Immunorelated gene polymorphisms associated with acute myeloid leukemia.
Liu Q; Hua M; Yan S; Zhang C; Wang R; Yang X; Han F; Hou M; Ma D
Clin Exp Immunol; 2020 Sep; 201(3):266-278. PubMed ID: 32349161
[TBL] [Abstract] [Full Text] [Related]
10. B-cell-specific irf4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.
Asslaber D; Qi Y; Maeding N; Steiner M; Denk U; Höpner JP; Hartmann TN; Zaborsky N; Greil R; Egle A
Blood; 2019 Nov; 134(20):1717-1729. PubMed ID: 31537531
[TBL] [Abstract] [Full Text] [Related]
11. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
12. [Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].
Kogure Y; Kataoka K
Rinsho Ketsueki; 2018; 59(10):2127-2135. PubMed ID: 30305518
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
Kataoka K; Iwanaga M; Yasunaga JI; Nagata Y; Kitanaka A; Kameda T; Yoshimitsu M; Shiraishi Y; Sato-Otsubo A; Sanada M; Chiba K; Tanaka H; Ochi Y; Aoki K; Suzuki H; Shiozawa Y; Yoshizato T; Sato Y; Yoshida K; Nosaka K; Hishizawa M; Itonaga H; Imaizumi Y; Munakata W; Shide K; Kubuki Y; Hidaka T; Nakamaki T; Ishiyama K; Miyawaki S; Ishii R; Nureki O; Tobinai K; Miyazaki Y; Takaori-Kondo A; Shibata T; Miyano S; Ishitsuka K; Utsunomiya A; Shimoda K; Matsuoka M; Watanabe T; Ogawa S
Blood; 2018 Jan; 131(2):215-225. PubMed ID: 29084771
[TBL] [Abstract] [Full Text] [Related]
14. Genetic alterations in adult T-cell leukemia/lymphoma.
Kogure Y; Kataoka K
Cancer Sci; 2017 Sep; 108(9):1719-1725. PubMed ID: 28627735
[TBL] [Abstract] [Full Text] [Related]
15. Diagnosis and classification of hematologic malignancies on the basis of genetics.
Taylor J; Xiao W; Abdel-Wahab O
Blood; 2017 Jul; 130(4):410-423. PubMed ID: 28600336
[TBL] [Abstract] [Full Text] [Related]
16. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract] [Full Text] [Related]
17. Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel.
Shindo H; Yasui K; Yamamoto K; Honma K; Yui K; Kohno T; Ma Y; Chua KJ; Kubo Y; Aihara H; Ito T; Nagayasu T; Matsuyama T; Hayashi H
Cytokine; 2011 Dec; 56(3):564-72. PubMed ID: 21890374
[TBL] [Abstract] [Full Text] [Related]
18. irf4 mutations in chronic lymphocytic leukemia.
Havelange V; Pekarsky Y; Nakamura T; Palamarchuk A; Alder H; Rassenti L; Kipps T; Croce CM
Blood; 2011 Sep; 118(10):2827-9. PubMed ID: 21791429
[TBL] [Abstract] [Full Text] [Related]
19. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
McMillin DW; Delmore J; Weisberg E; Negri JM; Geer DC; Klippel S; Mitsiades N; Schlossman RL; Munshi NC; Kung AL; Griffin JD; Richardson PG; Anderson KC; Mitsiades CS
Nat Med; 2010 Apr; 16(4):483-9. PubMed ID: 20228816
[TBL] [Abstract] [Full Text] [Related]
20. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract] [Full Text] [Related]
